ELI LILLY AND COMPANY Increase (Decrease) in Prepaid Expense and Other Assets
ELI LILLY AND COMPANY (LLY) reported Increase (Decrease) in Prepaid Expense and Other Assets of $6.61 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-02-12
- ELI LILLY AND COMPANY increase (decrease) in prepaid expense and other assets for fiscal 2025 was $6.61B, a 98.41% increase from fiscal 2024.
- ELI LILLY AND COMPANY increase (decrease) in prepaid expense and other assets for fiscal 2024 was $3.33B, a 3.53% decline from fiscal 2023.
- ELI LILLY AND COMPANY increase (decrease) in prepaid expense and other assets for fiscal 2023 was $3.45B, a 335.16% increase from fiscal 2022.
- ELI LILLY AND COMPANY increase (decrease) in prepaid expense and other assets for fiscal 2022 was $793.50M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|
| 2025-12-31 | $6.61B 10-K · filed 2026-02-12 | |
| 2024-12-31 | $3.33B 10-K · filed 2026-02-12 | $3.33B 10-K · filed 2025-02-19 |
| 2023-12-31 | $3.45B 10-K · filed 2026-02-12 | $3.45B 10-K · filed 2025-02-19 |
| 2022-12-31 | $793.50M 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |